Rubius Therapeutics Net Income

Rubius Therapeutics posts a net income of $-230M as of December 2022. That compares with $-200M in the prior-year period — down 18.9% year over year. That is below the Healthcare sector average of $16B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Rubius Therapeutics's net income was $-200M. The latest reading is $-230M — a 18.9% year-over-year decrease (period ending December 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a net income near $16B is typical. Rubius Therapeutics's $-230M is lower that level. That is roughly 101.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Rubius Therapeutics's financial statement story. At $-230M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for RUBY's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $16B), and (3) consistency with growth and profitability. This page covers the first two; Rubius Therapeutics's other metric pages and overview cover the third.